课题基金 / 基金详情

Proteomic analysis of AML1/RUNX1 mutant complexes

Proteomic analysis of AML1/RUNX1 mutant complexes
AML1/RUNX1 突变体复合物的蛋白质组学分析
批准号:
15591008
负责人:
HARADA Hironori
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

HARADA Hironori的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Myelodysplastic syndrome(MDS) is a clonal disorder of hematopoietic stem cells characterized by ineffective and inadequate hematopoiesis. MDS in a subset of patients arise after previous chemotherapy or radiation exposure for other malignancies. As MDS is a heterogeneous disorder, specific gene abnormalities playing a role in the myelodysplastic process have been difficult to identify. In this study, we analyzed the somatic mutations in the AML1/RUNX1 gene, which is a critical regulator of definitive hematopoiesis and the most frequent targets for translocation of acute myeloid leukemia (AML), in patients with MDS. We detected AML1 point mutations in 26 of 110(23.6%) patients with refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEBt) and AML following MDS (defined these categories as MDS/AML). Among 22 patients with radiation-related (including 14 atomic bomb survivors) and/or therapy-related MDS/AML, 11(50%) patients had the AML1 mutations mostly in N-terminal re … More gion. In contrast, 15 of 88(17%) patients with sporadic MDS/AML showed the AML1 mutations equally in both N-terminal and C-terminal region. The MDS/AML patients with AML1 mutations had a significantly worse prognosis than those without AML1 mutations. Most of AML1 mutants lost trans-activation potential, regardless of their DNA binding potential. These data suggested that AML1 point mutation is one of the major driving forces of MDS/AML, and these mutations may represent a distinct clinicopathologic-genetic entity.To clarify mechanisms of the AML1 dysfunctions, we established cell lines stably expressing FLAG-tagged wild-type or mutant AML1 proteins. A complex of transcriptional factors including these AML1 proteins were purified by immunoprecipitation with an anti-FLAG antibody, and then were analyzed by MALDI-TOF/TOF analyzer. We identified CBFβ,ets-1,p300,C/EBPα and GATA-1 in the complex with wild-type AML1 as well as previous studies using different methods. However, other proteins were identified in the complex with mutated-AML1. We have been analyzing the direct binding ability of AML1 to these proteins. Less
期刊论文(38)
专著(0)
科研奖励(0)
会议论文
MDSにおけるAML1/RUNX1遺伝子異常の意義
AML1/RUNX1 基因异常在 MDS 中的意义
DOI: --
发表时间: 2005
期刊: 血液・腫瘍科 50(1)
影响因子: --
作者: [原田浩徳, 原田結花]
通讯作者: 原田結花
Somatic mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome. Takaku F, et al.eds.
与骨髓增生异常综合征相关的 AML1/RUNX1 基因体细胞突变。
DOI: --
发表时间: 2005
期刊: Annual Review of Hematology 2005 (Chugai Igaku-sya, Tokyo)
影响因子: --
作者: [Harada H, et al.]
通讯作者: et al.
Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome
与骨髓增生异常综合征相关的 AML1/RUNX1 基因点突变
DOI: --
发表时间:
期刊: Critical Reviews (in press)
影响因子: --
作者: [Harada H, Harada Y]
通讯作者: Harada Y
MDSにおけるAML1/RUNX1変異 Annual Review血液2005
2005 年 MDS 年度血液审查中的 AML1/RUNX1 突变
DOI: --
发表时间: 2005
期刊:
影响因子: --
作者: [原田浩徳, 原田結花(分担執筆)(高久文麿他編)]
通讯作者: 原田結花(分担執筆)(高久文麿他編)
14
    Molecular mechanisms of myelodysplastic syndromes (MDS) using RUNX1-mutated iPS cells derived from familial MDS patients
    Establishment of new classification in myeloid neoplasms for personalized medicine
    • 批准号:
      21591206
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2009
    • 负责人:
      HARADA Hironori
    • 依托单位:
    AML1 point mutations play a pivotal role in the pathogenesis of MDS/AML
    • 批准号:
      19591114
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2007
    • 负责人:
      HARADA Hironori
    • 依托单位:
    Genetic pathway in molecular pathogenesis of myelodysplastic syndrome
    • 批准号:
      17590998
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2005
    • 负责人:
      HARADA Hironori
    • 依托单位:
    国内基金
    海外基金
    RUNX1通过BMP2/Smad信号轴调控肿瘤相关巨噬细胞M2极化促进膀胱癌进展的机制研究
    • 批准号:
      2026JJ81626
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      黎勇林
    • 依托单位:
    三尖刺血经RUNX1下调CMPK2磷酸化减轻Ox-mtDNA介导的小胶质细胞炎症反应治疗急性缺血性卒中的机制研究
    USP11/RUNX1正反馈环路抑制免疫原性细胞死亡促进结直肠癌进展的机制研究
    • 批准号:
      JCZRQN202501352
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
    • 依托单位:
    化瘀解毒方调控RUNX1介导自噬依赖性NETosis改善急性脑梗死的机制研究
    • 批准号:
      2025JJ50566
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      李定祥
    • 依托单位: